A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI.

Eva Svehlikova; Christina Gatschelhofer; B Lackner; M Ratzer; Gabriele Fluhr; A Stoisser; DJ Gerring; J Jezek; S Howell; L Zakrzewski; Thomas Pieber

A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI.

Eva Svehlikova (Erstautor*in)
, Christina Gatschelhofer
, B Lackner
, M Ratzer
, Gabriele Fluhr
, A Stoisser
, DJ Gerring
, J Jezek
, S Howell
, L Zakrzewski
, Thomas Pieber

Klinische Abteilung für Endokrinologie und Diabetologie

Publikation: Beitrag in Fachzeitschrift › Konferenzabstract

Originalsprache	Englisch
Fachzeitschrift	Diabetologia
Publikationsstatus	Veröffentlicht - 2025
Veranstaltung	61st EASD Annual Meeting of the European Association for the Study of Diabetes - Vienna, Österreich Dauer: 15 Sep. 2025 → 19 Sep. 2025

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

301 Medizinisch-theoretische Wissenschaften, Pharmazie
302 Klinische Medizin
305 Andere Humanmedizin, Gesundheitswissenschaften

Andere Dateien und Links

Web of Science

A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI.
Svehlikova, E. (Vortragende), Gatschelhofer, C. (Autor*in), Lackner, B. (Autor*in), Ratzer, M. (Autor*in), Fluhr, G. (Autor*in), Stoisser, A. (Autor*in), Gerring, D. (Autor*in), Jezek, J. (Autor*in), Howell, S. (Autor*in), Zakrzewski, L. (Autor*in) & Pieber, T. (Autor*in)
2025
Aktivität: Vortrag oder Poster › Poster

Dieses zitieren

@article{1500c39e9615493b93a630aaed3b3924,

title = "A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI.",

author = "Eva Svehlikova and Christina Gatschelhofer and B Lackner and M Ratzer and Gabriele Fluhr and A Stoisser and DJ Gerring and J Jezek and S Howell and L Zakrzewski and Thomas Pieber",

year = "2025",

language = "English",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Science and Business Media Deutschland GmbH",

note = "61st EASD Annual Meeting of the European Association for the Study of Diabetes ; Conference date: 15-09-2025 Through 19-09-2025",

}

TY - JOUR

T1 - A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI.

AU - Gatschelhofer, Christina

AU - Lackner, B

AU - Ratzer, M

AU - Fluhr, Gabriele

AU - Stoisser, A

AU - Gerring, DJ

AU - Jezek, J

AU - Howell, S

AU - Zakrzewski, L

AU - Pieber, Thomas

A2 - Svehlikova, Eva

PY - 2025

Y1 - 2025

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:1583384802110

M3 - Conference abstract

SN - 0012-186X

JO - Diabetologia

JF - Diabetologia

T2 - 61st EASD Annual Meeting of the European Association for the Study of Diabetes

Y2 - 15 September 2025 through 19 September 2025

ER -

A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI.

UN SDGs

Wissenschaftszweige

Andere Dateien und Links

Aktivitäten

A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI.

Dieses zitieren